乌司他丁对重症胰腺炎患者血清hs—CRP和预后影响.docVIP

乌司他丁对重症胰腺炎患者血清hs—CRP和预后影响[摘要] 目的 观察乌司他丁对重症胰腺炎患者的疗效，以及对其血清hs—CRP的影响。 方法 80例重症胰腺炎患者随机分为治疗组和对照组，各40例，两组患者均予常规营养对症支持治疗，治疗组在此基础给予乌司他丁30万U，静滴，每天1次，连用1周，比较两组的疗效以及腹痛/腹胀消失时间、退热时间、住院时间、预后（死亡率）及治疗前后血淀粉酶及hs—CRP的变化。 结果 治疗组总有效率达90.0%，对照组总有效率达72.5%，治疗组明显优于对照组（P 0.05）。治疗组患者腹痛/腹胀消失时间及退热时间、住院时间均明显短于对照组，且治疗组患者预后好，死亡率低。治疗组及对照组的血淀粉酶、hs—CRP治疗后均较治疗前显著降低，且治疗组降低更明显（P 0.05）。 结论 乌司他丁治疗重症胰腺炎疗效确切，可以抑制炎症反应，考虑可能通过降低hs—CRP而发挥作用，且能明显改善SAP患者的预后。 [关键词] 重症胰腺炎；乌司他丁；hs—CRP；预后 [中图分类号] R576 [文献标识码] B [文章编号] 1673—9701（2012）26—0070—02 Serum hs—CRP and prognosis of Ulinastatin on patients with severe pancreatitis SHEN Quanwen Department of Internal Medicine，Wuzhong Peoples Hospital of Suzhou City in Jiangsu Province，Suzhou 215128，China [Abstract] Objective To explore the efficacy of Ulinastatin on patients with severe pancreatitis， as well as to observe the changes of their serum hs—CRP. Methods All 80 cases severe pancreatitis were randomly divided into treatment group and control group 40 cases，all the patients were given traditional nutrition support therapy，on the basis of traditional treatment，the treatment group was given ulinastatin D 300 000 units，intravenous infusion，every day times a day for one week. the efficacy as well as abdominal pain，bloating disappeared，fever clearance time，duration of hospitalization，and prognosis （mortality） before and after treatment the blood of amylase and of hs—CRP changes were all compared between wo groups. Results The total effective rate of the treatment group was 90.0%，total effective rate of the control group was 72.5%， treatment group was significantly better than the control group （P 0.05）. Patients of the treatment group treated with abdominal pain，bloating disappear time and cooling time，hospital stay were significantly shorter than the control group， and a better prognosis in patients treated with low mortality. Serum amylase treatment group and control group of hs—CRP after treatment than before treatment was significantly lower，and the treat